Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
about
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondMLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemiaDOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemiaPerspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Epigenetic modifiers in normal and malignant hematopoiesis.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.SAM/SAH Analogs as Versatile Tools for SAM-Dependent Methyltransferases.Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Functional interdependence of BRD4 and DOT1L in MLL leukemia.Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid LeukemiaPBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
P2860
Q34667249-00D67546-C373-4DDE-94A7-603A5B6FF620Q35824823-280FD3FE-463D-447F-95DE-3FE9AA886666Q35967446-4F732B21-195A-488C-BB97-74F4163DBB83Q36737896-AE013C79-80DC-4DA3-BA19-65CAA7598F05Q37188783-2F705053-A5C5-45C4-B2EF-C301CFFDEB0DQ38428692-E1EF5DB8-27F9-4C47-9766-3DF6D85F74C2Q38459868-0375819B-1CF4-4165-B0A0-CCBB43F42EBEQ38537883-CDDD9E7B-F66A-4728-903D-A8CCFB3EC039Q38625953-CD7D9F42-E4BD-43D9-83C8-3304682FE5DBQ38641649-DDB52325-9257-4FA0-8C16-87EB30642781Q38826127-7666F46F-6912-46D4-BE7C-BEDEFD80942BQ39381251-CF47BD96-F5D7-4DAD-9DF3-7C3C98563428Q39688289-F6DC6358-02A1-4807-BEF7-F59433CB8208Q42694670-B4833600-308B-4F8A-B1CD-1F79BB37A543Q48272949-9D76E770-9020-4589-84A7-A06560420F63Q48809898-6D2CFF47-4EAA-4A77-B97E-8CF5FFB0E7EFQ51818965-1DEB93A8-CCC8-48C8-B9D8-82D23C98F0A1
P2860
Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@ast
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@en
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@nl
type
label
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@ast
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@en
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@nl
prefLabel
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@ast
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@en
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@nl
P2093
P2860
P356
P1433
P1476
Primary acute myeloid leukemia ...... to a DOT1L inhibitor in vitro
@en
P2093
M J Christopher
S M Sarkaria
P2860
P2888
P304
P356
10.1038/LEU.2014.235
P577
2014-07-31T00:00:00Z
P5875
P6179
1042496830